Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 16;15(8):e43598.
doi: 10.7759/cureus.43598. eCollection 2023 Aug.

A Case of Docetaxel-Induced Left Ventricular Outflow Tract Obstruction

Affiliations
Case Reports

A Case of Docetaxel-Induced Left Ventricular Outflow Tract Obstruction

Taiga Mase et al. Cureus. .

Abstract

Docetaxel, a taxoid chemotherapy agent, may induce fluid retention. We present a case of metastatic breast cancer in which high output caused by docetaxel-induced fluid retention resulted in heart failure due to left ventricular outflow tract (LVOT) obstruction. A 58-year-old woman presented with exertional dyspnea and anasarca. The jugular venous pressure was elevated, and the carotid pulse was pulsus bisferiens with a spike-and-dome configuration. On auscultation, a mid-late systolic murmur that did not radiate to the neck but increased with the Valsalva maneuver was noted. Echocardiography revealed a left ventricular ejection fraction of 63% with systolic anterior motion (SAM) of the mitral valve, resulting in LVOT obstruction with a resting pressure gradient of 64 mmHg and moderate to severe mitral regurgitation. Treatment with carvedilol, trichlormethiazide, and an increased dose of furosemide gradually improved her symptoms, physical findings, and echocardiographic abnormalities. This case highlights the importance of recognizing high-output heart failure along with LVOT obstruction in patients scheduled to receive docetaxel.

Keywords: docetaxel; fluid retention; heart failure; high-output; left ventricular outflow tract.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Echocardiography
Apical three-chamber views at end-diastole (A) and end-systole (B) show SAM of the mitral valve (arrow). Color Doppler images of an apical three-chamber view (C) and four-chamber view (D) show an LVOT obstruction, along with mitral regurgitation (arrowheads), with a peak flow velocity of 4.0 m/s (E) Ao: aorta, LA: left atrium, LV: left ventricle

References

    1. Docetaxel: a review of its pharmacology and clinical activity. Trudeau ME. https://pubmed.ncbi.nlm.nih.gov/8853517/ Can J Oncol. 1996;6:443–457. - PubMed
    1. Docetaxel: a review of its use in metastatic breast cancer. Lyseng-Williamson KA, Fenton C. Drugs. 2005;65:2513–2531. - PubMed
    1. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience. van Oosterom AT, Schrijvers D, Schriivers D [corrected to Schrijvers D] Anticancer Drugs. 1995;6:356–368. - PubMed
    1. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. Semb KA, Aamdal S, Oian P. J Clin Oncol. 1998;16:3426–3432. - PubMed
    1. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. Piccart MJ, Klijn J, Paridaens R, et al. J Clin Oncol. 1997;15:3149–3155. - PubMed

Publication types

LinkOut - more resources